Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia-Reference-Cited by-同舟云学术

Characterization of a multidisciplinary team’s role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia

Published:2023-03-21 Issue:4 Volume:31 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Pervitsky Vera,Guglielmo Julie,Moskoff Benjamin,Kneen Roxie,Leija Carol,Sawicky Deborah,Krackeler Margaret Li,Jonas Brian A.^ORCID,Beechinor Ryan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-023-07664-z.pdf

Reference28 articles.

1. Acute Myeloid Leukemia Treatment (PDQ®). NIH National Cancer Institute. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq. Published 2021. Accessed 25 Sept 2021

2. Leukemia - acute myeloid - AML: statistics. https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics. Accessed 25 Sept 2021

3. DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383(7):617–629. https://doi.org/10.1056/NEJMoa2012971

4. Altman JK, Lurie RH, Appelbaum FR et al (2021) NCCN guidelines acute myeloid leukemia (age ≥ 18 years). NCCN 3.2021

5. DiNardo CD, Maiti A, Rausch CR et al (2020) 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724–e736. https://doi.org/10.1016/S2352-3026(20)30210-6

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies;Cancers;2023-09-18